Clinical trials
Chronic Liver Disease and Cirrhosis clinical trials
Below are recruiting chronic liver disease and cirrhosis clinical trials, each written for real people, not researchers. We’re tracking 203 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05333471RecruitingPhase 1/Phase 2
Fecal transplant for chronic bowel inflammation in CGD
This study tests whether transplanting stool microbiome (fecal microbiota transplant) can improve chronic colitis in people with chronic granulomatous disease (CGD). It aims to reduce bowel inflammation and symptoms by changing gut bacteria.
Bethesda, MarylandAges 10–60 - NCT05844462RecruitingPhase 3
Tadalafil for severe lung blood-pressure problems from COPD
This study tests whether tadalafil can improve outcomes for people with severe pulmonary hypertension caused by COPD (chronic lung disease). It compares how you do with tadalafil versus standard care, focusing on breathing symptoms and how well your heart and lungs cope.
Le Kremlin-Bicêtre, FranceAges 18–85 - NCT04899102Recruiting
Intermittent fasting for fatty liver disease in adults
This study tests whether intermittent fasting can improve fatty liver disease (NAFLD) by reducing liver fat. It focuses on adults with confirmed fatty liver and extra liver fat seen on a special MRI scan.
Boston, MassachusettsAges 18 years+ - NCT07325526RecruitingPhase 2
Testing a new drug for liver cirrhosis from fatty liver disease
This trial tests if a new medicine, BI 3802876, is safe and tolerable for people with compensated liver cirrhosis caused by MASH (a type of fatty liver disease). Participants must have early-stage cirrhosis without complications like fluid buildup or bleeding.
Chandler, ArizonaAges 18–75 - NCT04446832Recruiting
Vaccine study for people waiting for liver transplant
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
LyonAges 18 years+ - NCT07286643Recruiting
Ultrasound-guided sepsis care for patients with cirrhosis
This study tests whether using a special ultrasound of the heart can guide treatment for sepsis-related low blood pressure in patients with cirrhosis. It aims to improve care and outcomes for critically ill patients.
ChandigarhAges 18–65 - NCT05870007Enrolling by invitationPhase 2
Atorvastatin and alkalizing treatment for autosomal dominant PKD
This Phase 2 study tests whether atorvastatin plus an “alkalizing” treatment (sodium bicarbonate) can slow or improve disease effects in people with autosomal dominant polycystic kidney disease (ADPKD). It specifically targets metabolic acidosis (when the body becomes “too acidic”), which may worsen kidney health.
New Taipei CityAges 18 years+ - NCT06798948RecruitingPhase 2
Can a mix of herbs improve mild fatty liver?
This study is testing if a combination of four herbs (artichoke, milk thistle, turmeric, and licorice root) can help people with non-alcoholic mild to moderate fatty liver disease (also called metabolic-associated fatty liver disease). It's a randomized trial, meaning participants are assigned to either the herbal mix or a comparison group. This may offer a natural option to support liver health.
Hangzhou, Select...Ages 18–65 - NCT05195450Recruiting
Tenofovir to stop liver disease in mild hepatitis B
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT07487727RecruitingPhase 3
Study of an experimental anemia drug for chronic kidney disease patients not on dialysis
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07002827Recruiting
Growth factors for early decompensated cirrhosis
This study tests whether a combination of two medicines (G-CSF and darbepoetin) given in one or more cycles can improve the body's immune and metabolic health in people with early-stage decompensated cirrhosis (advanced liver disease with mild complications). It compares these treatments with standard medical care.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Peoria, ArizonaAges 18 years+ - NCT06836609RecruitingPhase 1/Phase 2
Study of a new drug for fatty liver disease (MASLD/MASH)
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
Chandler, ArizonaAges 18–65 - NCT07652151Recruiting
Fatty Liver Disease Study Using Wearable Tracking
This research studies fatty liver disease linked to metabolic problems like diabetes and obesity. You'll wear a fitness tracker and have liver imaging to help doctors understand the disease and find new treatments.
RomaAges 18 years+ - NCT07603817Recruiting
Thyroid Disease and Fatty Liver Disease Study
This study looks at the connection between thyroid problems (especially when the thyroid doesn't make enough hormone) and a common liver condition where fat builds up in the liver. Researchers want to understand how these two conditions relate to each other in people without diabetes.
Sohag, Sohag GovernorateAges 18 years+ - NCT07355868RecruitingEarly Phase 1
Cell therapy for COPD
This trial is testing a new type of cell therapy called REGEND007 for people with COPD. It looks at whether the treatment can help improve how far you can walk and your overall breathing.
Yiwu, ZhejiangAges 40–80 - NCT06152250Recruiting
Fatty liver inflammation study with liver biopsy
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT05199259Recruiting
Blood test study for people at risk for or with liver cancer
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
Escondido, CaliforniaAges 18 years+ - NCT07494409RecruitingPhase 3
A new oral medicine for anemia in dialysis patients
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
ShanghaiAges 18–75 - NCT04873102RecruitingPhase 2
Danazol for low blood counts in some people with cirrhosis
This Phase 2 study tests danazol to improve low blood counts (low white blood cells and/or low platelets) in people with certain types of cirrhosis. It also looks at who may benefit, especially those with specific inherited blood-telomere changes.
Los Angeles, CaliforniaAges 18 years+ - NCT05346393Recruiting
TIPS procedure for kidney failure in people with cirrhosis
This trial studies whether a liver procedure called TIPS can help people with cirrhosis who develop sudden kidney failure (HRS-AKI). It aims to improve kidney function and overall outcomes, but participation depends on several safety checks.
AachenAges 18–80 - NCT06092385Recruiting
Swiss cirrhosis study for liver patients and controls
This study compares patients with advanced liver scarring (cirrhosis) to healthy controls to learn more about the condition. It may help researchers better understand and manage liver disease.
Lugano, Canton TicinoAges 18 years+ - NCT03267615Recruiting
Study in advanced liver scarring using pressure and stiffness tests
This study looks at people over 18 who have advanced, long-term liver scarring. It uses specialized measurements of liver stiffness and pressure to confirm eligibility and may help doctors better understand this condition.
ViennaAges 18–100 - NCT07417553RecruitingPhase 2
Hydronidone capsules for hepatitis B-related liver scarring
This study tests a new capsule called hydronidone for people with liver scarring caused by chronic hepatitis B. You must already be on stable hepatitis B treatment and have moderate to advanced scarring.
Chongqing, Chongqing MunicipalityAges 18–70
Hear when a new Chronic Liver Disease and Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease and cirrhosis?
- Yes. Clin2 currently lists 203 recruiting chronic liver disease and cirrhosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease and cirrhosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease and cirrhosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.